Prostate specific membrane antigen (PSMA) is a 750 amino acid cell surface glycoprotein, membrane bound binuclear zinc metallopeptidase. It is the most promising enzyme biomarker for detection of prostate cancer (PC) and therapeutic target, to date. It has been demonstrated that over-expressed PSMA is correlated with reduced recurrence free survival.
Gallium PSMA-11 PET/CT is now a standard imaging test for men with biochemical recurrence in Germany, and has shown significantly better results than F-Choline PET in detection of metastasis and relapses. The major advantages of Ga-PSMA-PET/CT are the good specificity and sensitive detection of lesions at low PSA, of small lymph node metastasis, and of central bone and liver metastasis.
Dr. Hadaschik concluded his presentation mentioning some future directions, including the new F-PMSA-1007 PET/CT and the concept of radioligandotherapy with Lutetium showing good overall response in current trials.
Speaker: Boris Hadaschik
Written by: Hanan Goldberg, MD, Urologic Oncology Fellow (SUO), University of Toronto, Princess Margaret Cancer Centre.Twitter: @GoldbergHanan at the 37th Congress of Société Internationale d’Urologie - October 19-22, 2017- Lisbon, Portugal